-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IdRgIdeDG5Fl84XUrj7QSz0UCEOmRceAbA7BDox/2g26+qxwbQ5PGzGM8GXQuo6O gySIZUB9eei57tRef6rsVQ== 0000897101-06-002628.txt : 20061219 0000897101-06-002628.hdr.sgml : 20061219 20061219165809 ACCESSION NUMBER: 0000897101-06-002628 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061219 FILED AS OF DATE: 20061219 DATE AS OF CHANGE: 20061219 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CNS INC /DE/ CENTRAL INDEX KEY: 0000814258 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411580270 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: PO BOX 39802 CITY: MINNEAPOLIS STATE: MN ZIP: 55439 BUSINESS PHONE: 6128206696 MAIL ADDRESS: STREET 1: PO BOX 39802 STREET 2: PO BOX 39802 CITY: MINNEAPOLIS STATE: MN ZIP: 55439 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PERKINS RICHARD W CENTRAL INDEX KEY: 0001030317 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-16612 FILM NUMBER: 061287121 BUSINESS ADDRESS: STREET 1: 730 EAST LAKE STREET CITY: WAYZATA STATE: MN ZIP: 55391 BUSINESS PHONE: 9524738367 MAIL ADDRESS: STREET 1: 730 EAST LAKE STREET CITY: WAYZATA STATE: MN ZIP: 55391 4 1 cns064947perkins_4ex.xml FORM 4 X0202 4 2006-12-19 1 0000814258 CNS INC /DE/ CNXS 0001030317 PERKINS RICHARD W 7615 SMETANA LANE EDEN PRAIRIE MN 55344 1 0 0 0 Common Stock 2006-12-19 4 D 0 72039 D 0 D Stock Option (Option to Buy) 11.37 2006-12-19 4 D 0 15000 26.13 D 2013-10-13 Common Stock 15000 0 D Stock Option (Option to Buy) 21.38 2006-12-19 4 D 0 5985 16.12 D 2016-05-01 Common Stock 5985 0 D Shares disposed of pursuant to an Agreement and Plan of Merger dated as of October 8, 2006 among GlaxoSmithKline plc, Platform Acquisition Corporation and CNS, Inc., as amended, pursuant to which each share of CNS common stock issued and outstanding at the effective time of the merger was converted into the right to receive $37.50 per share in cash, less applicable withholding tax and without interest. At the effective time of the merger pursuant to an Agreement and Plan of Merger dated as of October 8, 2006 among GlaxoSmithKline plc, Platform Acquisition Corporation and CNS, Inc., as amended, all of the CNS stock options outstanding became fully vested, were cancelled and were converted into the right to receive the excess, if any, of $37.50 over the exercise price of the stock option for each share of CNS common stock subject to the option, less applicable withholding tax and without interest. /s/ By Michael Weber, Attorney-In-Fact 2006-12-19 -----END PRIVACY-ENHANCED MESSAGE-----